We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Test Stratifies Patients with Bladder Cancer Symptoms

By LabMedica International staff writers
Posted on 01 Jun 2015
Print article
Image: Cxbladder kit, for the noninvasive laboratory test for the detection of bladder cancer (Photo courtesy of Peter Wren-Hilton).
Image: Cxbladder kit, for the noninvasive laboratory test for the detection of bladder cancer (Photo courtesy of Peter Wren-Hilton).
A urine-based molecular diagnostic combines clinical risk factors and gene expression biomarkers to accurately triage patients presenting with blood in their urine (hematuria) who have a low probability of urothelial cancer (UC or bladder cancer).

Hematuria can be symptomatic of UC and ruling out patients with benign causes of such bleeding during primary evaluation is challenging. Patients with hematuria must typically undergo a full urological workup to investigate the possibility of bladder cancer, with a corresponding increase in the overall clinical and financial burden of these patients on health care systems.

Urologists at Palmerston North Hospital (New Zealand) working with a commercial company collected data from 587 patients with macrohematuria. Expression of five genes in a voided urine sample (genotypic) and age, gender, frequency of macrohematuria and smoking history (phenotypic) was analyzed. To provide gene expression data, a single mid-stream urine sample was collected from participants using the Urine Sampling System. Multigene analysis of samples from all studies was carried out in accordance with the standard operating procedure, as is used for the commercially available multigenic test.

Both urine sampling system and the multigenic Cxbladder Triage test are products of Pacific Edge Ltd. (Dunedin, New Zealand). Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic and clinical risk factors to accurately identify and remove patients with hematuria who have a low probability of bladder cancer, from needing to have a full-urological work-up. In total, samples from 587 patients were available for modelling comprising 72 UC-positive and 515 UC-negative samples. A combined genotypic-phenotypic model (G + P INDEX) was compared with genotypic (G INDEX) and phenotypic (P INDEX) models. Area under receiver operating characteristic curves (AUC) defined the performance of each INDEX.

The G + P INDEX offered a bias-corrected AUC of 0.86 compared with 0.61 and 0.83, for the P and G INDEXs respectively. When the test-negative rate was 0.4, the G + P INDEX (sensitivity = 0.95; negative predictive value (NPV) = 0.98) offered improved performance compared with the G INDEX (sensitivity = 0.86; NPV = 0.96). In all 80% of patients with microhematuria who did not have UC were correctly triaged out using the G + P INDEX, therefore not requiring a full urological work-up.

David Gregory Darling, Chief Executive Officer of Pacific Edge, said, “This study shows that Cxbladder Triage can accurately identify those patients who have a low probability of UC with a high level of sensitivity (95%) and high negative predictive value NPV (98%). The use of this test will enable physicians to evaluate those patients presenting with hematuria, and quickly and accurately remove those with a low probability of cancer, thereby reducing the number of individuals who require an expensive and invasive full urological workup. The use of Cxbladder Triage will also allow clinicians to make effective choices about the deployment of their skills and capabilities on the patients who need it most.” The study was published on March 27, 2015, in the journal BMC Urology.

Related Links:

Palmerston North Hospital 
Pacific Edge Ltd. 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.